Clinical Trials
11
Active:0
Completed:1
Trial Phases
3 Phases
Phase 1:5
Phase 2:3
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (55.6%)Phase 2
3 (33.3%)Phase 3
1 (11.1%)DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
Phase 2
Recruiting
- Conditions
- Perianal Fistula Due to Crohn's Disease
- Interventions
- Biological: DB-3QBiological: Placebo
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Direct Biologics, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06918808
- Locations
- 🇺🇸
Columbia University Irving Medical Center/NYPH, New York, New York, United States
Study of ExoFlo for the Treatment of Perianal Fistulas
Phase 1
Terminated
- Conditions
- Perianal FistulaCrohn's Disease
- Interventions
- Other: Local injection of normal saline
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Direct Biologics, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT05836883
- Locations
- 🇺🇸
Direct Biologics Investigational Site, Los Angeles, California, United States
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
Phase 3
Recruiting
- Conditions
- Acute Respiratory Distress SyndromeARDS
- Interventions
- Other: Intravenous normal saline
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Direct Biologics, LLC
- Target Recruit Count
- 970
- Registration Number
- NCT05354141
- Locations
- 🇺🇸
Direct Biologics Investigational Site, Salt Lake City, Utah, United States
Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant Patients
- Conditions
- Solid Organ Transplant RejectionOrgan Rejection TransplantsOrgan Rejection
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Direct Biologics, LLC
- Registration Number
- NCT05215288
- Locations
- 🇺🇸
Direct Biologics Investigational Site, San Francisco, California, United States
Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis
Phase 1
Terminated
- Conditions
- Ulcerative ColitisInflammatory Bowel Diseases
- Interventions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Direct Biologics, LLC
- Target Recruit Count
- 4
- Registration Number
- NCT05176366
- Locations
- 🇺🇸
Direct Biologics Investigational Site, New York, New York, United States
- Prev
- 1
- 2
- 3
- Next
News
No news found